CE Mark for MEVION S250i Proton Therapy System
Mevion Medical Systems announced today that the MEVION S250i Proton Therapy System® has achieved CE Marking clearance. CE Marking permits clinical use of the system within the European Union and any country that recognizes the CE Mark. The MEVION S250i system includes HYPERSCAN™ technology, the next generation of pencil beam scanning (PBS) for faster, sharper, and more robust proton treatments.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171113005323/en/
The first European MEVION S250i proton therapy system installation will be completed in 2018 at the Zuid-Oost Nederland Protonen Therapie Centrum (ZON PTC) at the Maastro Clinic in Maastricht, the Netherlands. (Photo: Business Wire)
“This milestone is part of Mevion’s global expansion of cutting-edge compact proton therapy systems in Europe,” said Perjan Pleunis, Field VP of Business Development (EMEA). “Mevion has led the way in establishing compact proton therapy as the most technologically advanced and financially viable choice in proton therapy.” European CE Marking is the first regulatory clearance for the MEVION S250i system. Mevion also submitted for US FDA 510(k) clearance in September.
First European Installation
The first European MEVION S250i proton therapy system installation will be completed in 2018 at the Zuid-Oost Nederland Protonen Therapie Centrum (ZON PTC) at the Maastro Clinic in Maastricht, the Netherlands.
The MEVION S250i system will be the first of its kind in Europe. Designed to deliver faster, sharper, and more robust treatments, the HYPERSCAN PBS technology incorporates the fastest energy layer switching, optimized spot sizes, and the Adaptive Aperture™ proton multi-leaf collimator system. This capability provides dose gradient advantages with up to a three times sharper lateral penumbra reducing dose uncertainty at the edge of the tumor thus sparing healthy tissue and preventing unnecessary radiation to sensitive locations. This improved precision in delivery is combined with hyper-fast beam delivery reducing the sensitivity to motion that current PBS technologies face when treating moving lesions such as those in the thoracic cavity.
Built on Leading Compact Proton Therapy
The MEVION S250i system is based on Mevion’s high efficiency, low financial risk S250 Series platform. The core technology of the S250 Series includes the world’s only gantry mounted superconducting synchrocyclotron, a six degree-of-freedom treatment couch and advanced in-room IGRT imaging, all leveraged in the S250i system. This compact, fully integrated platform has years of successful clinical experience, proven financial viability and now delivers next generation pencil beam scanning.
The MEVION S250i lowers the cost per patient by reducing capital costs, reducing operating costs, and increasing treatment throughput. Mevion customers have achieved the fastest per-room patient ramp-up in the history of proton therapy. High throughput is achieved via linac-like workflow, low maintenance requirements, and industry-leading uptime. Demonstrating that compact proton therapy is a viable option for any size cancer center is core to Mevion’s mission of making proton therapy accessible to as many patients as possible.
About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in the Europe, Japan and China. For more information, please visit www.mevion.com.
Follow Mevion on Twitter: https://twitter.com/mevionmedical
Connect with Mevion on LinkedIn: https://www.linkedin.com/company/mevion-medical-systems
About the MEVION S250™ Series
The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefiting from Mevion’s patented Direct Dose™ beam delivery technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers.
The MEVION S250 Series includes:
- MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities
- MEVION S250i Proton Therapy System™ with HYPERSCAN™ technology, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed
- MEVION S250mx™ options, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime
The MEVION S250i Proton Therapy System is 510(k) pending and has not been cleared by the USFDA for clinical use.
Melanie Benton, 978-540-1551
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Porta Solutions Has Been Awarded as Excellence of the Year Innovation & Leadership for the Flexible Production at Le Fonti Awards 201721.11.2017 20:04 | Tiedote
Maurizio Porta, Porta Solutions’CEO triumphed at the 32th edition of the IAIR Awards. The Award Ceremony, held at the at London Stock Exchange on the 20th of October 2017, crowned him the Excellence of the Year, Innovation & Leadership, for the Flexible Production. For being an Italian excellence since 1958, innovative leader in the sector of productive flexibility in the manufacturing world. In particular to be able to aim continually and strategically on innovation and customization to ensure the best performance and highest quality. “Flexible Production: produce what you sell, no stock, no stress, more cash" says Maurizio Porta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005803/en/ Porta Solutions was awarded at the Le Fonti Awards (Photo: Business Wire) Today, the
China Global Investment Forum Hangzhou 2017 Opens21.11.2017 19:04 | Tiedote
On November 20, China Global Investment Forum Hangzhou 2017 opened. The forum was hosted by the Hangzhou Municipal People's Government and the Department of Commerce of Zhejiang Province, and organized by the Hangzhou Investment Promotion Bureau and Euromoney Institutional Investor PLC. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005723/en/ China Global Investment Forum Hangzhou 2017 Themed "Sharing the Opportunity of Hangzhou, Co-building a World-renowned City", the event brought together nearly 1,000 renowned experts, scholars and entrepreneurs from home and abroad, to interpret Hangzhou's economy, explore Hangzhou's future industries, look into the investment trends of the world and Hangzhou, and offer advice on improving Hangzhou's level of opening to the outside world, promoting
TechnipFMC, Saipem & Bureau Veritas Sign Partnership with Expert Teleportation21.11.2017 18:27 | Tiedote
BUREAU VERITAS, SAIPEM and TECHNIPFMC are teaming up to bring expert tele assistance to on-site operators within the specific context of the Oil & Gas sector (offshore, remote location, ATEX, IECEx, etc.) and have formed a collaborative partnership with EXPERT TELEPORTATION who will lead the project development. The 15-month long project will deliver a hands’ free device (modified smart glasses) adapted to use with personnel protective equipment. The adapted tool will connect an operator located on site anywhere in the world with a remote expert / analyst in real time via audio and video stream. This EXPERT TELEPORTATION project will enable higher operational efficiency, smarter and faster response time, improved safety and a reduced carbon footprint. ABOUT: In an increasingly competit
Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) from EMA in Newly Diagnosed Multiple Myeloma21.11.2017 17:40 | Tiedote
Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency (EMA), for the immunotherapy DARZALEX®▼ (daratumumab). The application seeks to broaden the existing marketing authorisation to include daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. “This submission to health authorities takes us one step closer to our goal of redefining combination therapy in multiple myeloma, with the potential to make daratumumab available to more patients throughout the treatment continuum: from newly diagnosed, to heavily pre-treated,” said Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen Europe, Middle East and Africa (EMEA). “We look forward to working closely with the
Andersen Global Announces Expansion in Uganda21.11.2017 17:30 | Tiedote
Andersen Global is proud to announce a presence in Uganda by way of a Collaboration Agreement with Ligomarc Advocates, a financial and corporate tax and legal firm. The firm is led by Managing Partner, Kabiito Karamagi. The addition of Ligomarc Advocates as a Collaborating Firm of Andersen Global continues the organization’s expansion in Africa. Ligomarc is Andersen Global’s fourth location in Africa. “Integrity, excellence, and putting the client at the center have always been of paramount importance to us, and our collaboration with Andersen Global will allow us to ensure our clients receive the best-in-class service internationally,” commented Kabiito Karamagi. “The team at Andersen shares our values of outstanding, seamless client service and independence—this is a natural fit.” Ligomarc Advocates was founded as a sole practice over fifteen years ago by Ruth Sebatindira,
Keio Plaza Hotel Tokyo Hosts "Sky Jazz Night" Events in the "Premier Grand" Club Lounge21.11.2017 17:00 | Tiedote
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host special jazz events for guests staying in our “Premier Grand” Club Floor on December 7, 8, 14, 15, and 16, 2017. A duo consisting of piano and contrabass artists will perform 30 minutes jazz sessions in our Club Lounge located on the 45th floor at 5:30p.m., 6:30p.m., and 7:30p.m. Guests listening to these jazz sessions can enjoy complimentary hors d’ oeuvres, and alcoholic and non-alcoholic beverages. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005017/en/ Club Floor "Premier Grand," Club Lounge (Photo: Business Wire) Our “Premier Grand” Club Floors were renovated and newly opened in December 2016, with guest rooms being fitted with various premium items
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme